Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10595033				
iling Date		2006-06-13				
irst Named Inventor Warre		en Ward				
Art Unit						
Examiner Name						
Mornoy Docket Number		WAW 0101 PUSA				

				Attorn	ey Doc	ket Number	WAW 0101 PU:	SA			
					U.S.	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1	4970081	A	1990-1	1-13	Frisbee, Steve	ns E				
If you wish	to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		_
			U.S.P	ATENT	APPLI	CATION PUBL	ICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines ant Passages o s Appear		
	1	20010042932	A1	2001-1	1-22	Chickering, Do	inald				
If you wish	n to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	ld button	Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns where Relevan Passages or Re Figures Appear	t elevant	T5
	1	2119244	GB		A	1983-11-16	Alza Corp				
	2	03005995	wo		A	2003-01-23	Aeropharm Techning.	ology			
If you wish	n to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_

	Application Number		10595033
NEODWATION DIGGS COURT	Filing Date		2006-06-13
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Warrer		en Ward
Not for submission under 37 CFR 1.99)	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	WAW 0101 PUSA

Examine Initials*	Cite No					
	1	SAITO K ET AL: "Effect of Ionic Interaction on the Entrapping of Drug Into Porous Microspheres and Drug Release Characteristics", Chemical and Pharmacoutical Bulletin, Pharmacoutical Society of Japan, Toriyo, JP. vol. 35, no. 5, Moy 1987 (1987-60), pages 2045-2051. Phytol 1625-263, Sp85: 0009-2263		1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

FXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Knd Codes of USPTO Patent Documents at year USPTO, GDV or MPEP 801.8.2 Effort office that issued the document, by the bo-batter code (WIPO Standard ST3.3) are full patent concerned, the shadoon of the year of the integration rate procedure the sent number of the submoor must procedure the sent number of the submoor incharge tooches the sent number of the submoor to counter. I kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 3 Applicant is to place a check mark their if English language the instalation is attached.

# Application Number | 1056033 | Fing Date | 2006-06-13 | Fing Date | 200

## Attorney Docket Number V

Please see 37	CFR 1.97:	and 1.98 to make the	appropriate selection(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inequiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/John E. Nemazı/	Date (YYYY-MM-DD)	2006-06-13
Name/Print	John E. Nemazi	Registration Number	30876

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2.11.450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.